Meaning
Administrative decrees issued by the State Council update the overarching statutory framework governing the evaluation, registration, manufacturing, and commercial distribution of medical devices within the People’s Republic of China. Formally promulgated as the revised Regulations on the Supervision and Administration of Medical Devices, nmpa order 739 codifies the national Medical Device Registrant System, separating commercial product ownership from physical manufacturing licenses. The decree grants the National Medical Products Administration extended enforcement powers, clarifies post-market surveillance duties, and introduces significant punitive fines tied directly to corporate revenue streams for safety violations.
Laboratory research equipment and general manufacturing consumables not designed for medical diagnosis, treatment, or therapy remain outside the direct remit of this order.
Registrant System
The regulatory system allows intellectual property holders to secure device registration certificates without constructing domestic manufacturing plants. Medical device registrants can contract certified contract manufacturing organizations across the mainland to fabricate products under valid quality management systems. The registrant retains absolute legal responsibility for product quality across the entire device lifecycle, managing design verification, clinical trials, and post-market vigilance.
This model enables foreign medical technology developers to outsource mainland assembly operations while holding device intellectual property through domestic corporate vehicles.
Registration Classes
Risk-based categorization schemes dictate the regulatory filing and approval pathways across three product classes. Class I devices, representing low personal risk, require an administrative record-filing dossier submitted to municipal-level medical product administrations without mandatory preliminary human trials. Class II devices require technical validation, safety testing, and formal approval by provincial-level drug administrations prior to commercial entry.
Class III devices, involving high bodily risk or life-supporting implants, undergo technical evaluations and national National Medical Products Administration reviews that require localized clinical evaluation reports.
Enforcement Punishments
Manufacturing or distributing unapproved medical devices triggers administrative fines scaling from fifteen to thirty times the total value of non-compliant products. Enterprise executives, legal representatives, and designated quality managers face personal fines up to three times their annual income earned during the non-compliant operational period. Violations cause the revocation of business licenses and impose ten-year or lifetime industry bans on accountable corporate personnel.
Unannounced inspections by regulatory authorities can halt factory lines upon the discovery of unapproved changes to manufacturing processes.